IL319922A - Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer - Google Patents
Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancerInfo
- Publication number
- IL319922A IL319922A IL319922A IL31992225A IL319922A IL 319922 A IL319922 A IL 319922A IL 319922 A IL319922 A IL 319922A IL 31992225 A IL31992225 A IL 31992225A IL 319922 A IL319922 A IL 319922A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- enzalutamide
- talazoparib
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (23)
1. Talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use in a method of treating metastatic castration-resistant prostate cancer in a subject in need thereof, for once daily orally administeration to a subject, wherein the administration of the talazoparib, or a pharmaceutically acceptable salt thereof, and the administration of the enzalutamide, or a pharmaceutically acceptable salt thereof, increases survival in the subject.
2. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 1, wherein the metastatic castration-resistant prostate cancer is metastatic castration-resistant prostate cancer with or without homologous recombination repair (HRR) gene mutations.
3. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 1 or claim 2, wherein the subject has not received: 1) systemic cancer treatment for non-metastatic castration-resistant prostate cancer or metastatic castration-resistant prostate cancer; 2) treatment with an androgen receptor signaling inhibitor, a PARP inhibitor, cyclophosphamide, or mitoxantrone for prostate cancer; or 3) treatment with platinum-based chemotherapy within 6 months or any history of disease progression on platinum-based therapy within 6 months.
4. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 3, wherein the subject is additionally receiving a gonadotropin releasing hormone analog or has had a bilateral orchiectomy.
5. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 4, wherein the gonadotropin releasing hormone analog is a gonadotropin releasing hormone agonist or a gonadotropin releasing hormone antagonist.
6. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 5, wherein the subject is unselected for DNA damage response (DDR) mutation status.
7. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 6, wherein survival is radiographic progression free survival.
8. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 7, wherein radiographic progression free survival is increased as compared to a subject who has received enzalutamide, or a pharmaceutically acceptable salt thereof, and placebo.
9. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 6, wherein survival is overall survival.
10. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 9, wherein overall survival is increased as compared to a subject who has received enzalutamide, or a pharmaceutically acceptable salt thereof, and placebo.
11. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 6, wherein survival is a significantly reduced risk of disease progression or death, as compared to a subject who has received enzalutamide, or a pharmaceutically acceptable salt thereof, and placebo.
12. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 11, wherein the significantly reduced risk of disease progression or death is at least a 37% reduction, as compared to a subject who has received enzalutamide, or a pharmaceutically acceptable salt thereof, and placebo.
13. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 12, wherein the talazoparib, or pharmaceutically acceptable salt thereof, is administered at a dosage equivalent to about 0.1 mg, about 0.25 mg, about 0.mg or about 0.5 mg once daily of talazoparib free base.
14. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 13, wherein the talazoparib, or pharmaceutically acceptable salt thereof, is administered at a dosage equivalent to about 0.35 mg once daily of talazoparib free base and further wherein the subject has moderate renal impairment.
15. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 14, wherein the talazoparib, or pharmaceutically acceptable salt thereof, is talazoparib tosylate.
16. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 15, wherein the enzalutamide, or pharmaceutically acceptable salt thereof, is administered at a dosage equivalent to about 160 mg once daily of enzalutamide free base.
17. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 16, wherein the dosage of enzalutamide, or a pharmaceutically acceptable salt thereof, is reduced, if enzalutamide, or a pharmaceutically acceptable salt thereof, is dosed concomitantly with a strong CYP2C8 inhibitor.
18. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 17, wherein the dose of enzalutamide, or a pharmaceutically acceptable salt thereof, is reduced to 80 mg once daily.
19. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 16, wherein the dose of enzalutamide, or a pharmaceutically acceptable salt thereof, is increased if the enzalutamide is dosed concomitantly with a CYP3A4 inducer.
20. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 19, wherein the dose of enzalutamide, or a pharmaceutically acceptable salt thereof, is increased to 240 mg daily.
21. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 20, wherein the enzalutamide, or a pharmaceutically acceptable salt thereof, is a free base.
22. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any of the preceeding claims, wherein the subject is a human.
23. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 22, wherein the human is an adult.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263412520P | 2022-10-02 | 2022-10-02 | |
| US202263434465P | 2022-12-21 | 2022-12-21 | |
| US202363445886P | 2023-02-15 | 2023-02-15 | |
| US202363470761P | 2023-06-02 | 2023-06-02 | |
| PCT/IB2023/059790 WO2024074959A1 (en) | 2022-10-02 | 2023-09-29 | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319922A true IL319922A (en) | 2025-05-01 |
Family
ID=90607623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319922A IL319922A (en) | 2022-10-02 | 2023-09-29 | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20260108513A1 (en) |
| EP (1) | EP4593828A1 (en) |
| JP (1) | JP2025533012A (en) |
| KR (1) | KR20250070114A (en) |
| CN (1) | CN120302972A (en) |
| AU (1) | AU2023357890A1 (en) |
| IL (1) | IL319922A (en) |
| MX (1) | MX2025003936A (en) |
| TW (1) | TWI883565B (en) |
| WO (1) | WO2024074959A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202600137A (en) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor and methods of treatment thereof |
| WO2026078615A1 (en) * | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078619A1 (en) * | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3372965D1 (en) | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| NZ564223A (en) | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| BRPI0709771B1 (en) | 2006-03-27 | 2022-01-25 | The Regents Of The University Of California | Compound and pharmaceutical composition |
| HUE035295T2 (en) | 2008-08-06 | 2018-05-02 | Medivation Technologies Inc | Poly (ADP-Ribose) Polymerase (PARP) Dihydropyridophthalazinone Inhibitors |
| AR078793A1 (en) | 2009-10-27 | 2011-12-07 | Orion Corp | DERIVATIVES OF NON-STEROID CARBOXAMIDS AND ACIL HYDRAZONE MODULATORS OF ANDROGENIC RECEPTORS OF SELECTIVE FABRIC (SARM), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF PROSTATE CANCER BETWEEN OTHERS |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| MX340319B (en) | 2010-02-08 | 2016-07-06 | Medivation Technologies Inc | Processes of synthesizing dihydropyridophthalazinone derivatives. |
| CN103282365B (en) | 2010-10-21 | 2017-12-29 | 麦迪韦逊科技有限公司 | (8S, 9R) 5 fluorine 8 (4 fluorophenyl) 9 (base of 1 methyl 1H, 1,2,4 triazoles 5) 8,9 dihydro 2H pyridos [4,3,2 de] phthalazines 3 (7H) ketone toluene fulfonate of crystallization |
| EP3066084A1 (en) | 2013-11-07 | 2016-09-14 | Medivation Technologies, Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
| EA201790290A1 (en) | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | FORMER SALTS (2S, 3S) -METHyl 7-Fluoro-2- (4-Fluoro-phenyl) -3- (1-Methyl-1H-1,2,4-TRIAZOL-5-IL) -4-Oxo-1,2 , 3,4-TETRAHYDROHINOLIN-5-CARBOXYLATE AND METHODS FOR PRODUCING THEM |
| CN108883115A (en) | 2015-10-26 | 2018-11-23 | 麦迪韦逊科技有限责任公司 | With PARP inhibitor for treating Small Cell Lung Cancer |
| AU2018347331A1 (en) | 2017-10-13 | 2020-04-09 | Merck Patent Gmbh | Combination of a PARP inhibitor and a PD-1 axis binding antagonist |
| EP4313034A1 (en) | 2021-03-24 | 2024-02-07 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
-
2023
- 2023-09-28 TW TW112137346A patent/TWI883565B/en active
- 2023-09-29 EP EP23800526.8A patent/EP4593828A1/en active Pending
- 2023-09-29 US US19/117,616 patent/US20260108513A1/en active Pending
- 2023-09-29 CN CN202380080015.0A patent/CN120302972A/en active Pending
- 2023-09-29 AU AU2023357890A patent/AU2023357890A1/en active Pending
- 2023-09-29 IL IL319922A patent/IL319922A/en unknown
- 2023-09-29 JP JP2025518772A patent/JP2025533012A/en active Pending
- 2023-09-29 WO PCT/IB2023/059790 patent/WO2024074959A1/en not_active Ceased
- 2023-09-29 KR KR1020257014482A patent/KR20250070114A/en active Pending
-
2025
- 2025-04-02 MX MX2025003936A patent/MX2025003936A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025533012A (en) | 2025-10-03 |
| AU2023357890A1 (en) | 2025-04-17 |
| TWI883565B (en) | 2025-05-11 |
| MX2025003936A (en) | 2025-05-02 |
| EP4593828A1 (en) | 2025-08-06 |
| KR20250070114A (en) | 2025-05-20 |
| TW202425975A (en) | 2024-07-01 |
| CN120302972A (en) | 2025-07-11 |
| WO2024074959A1 (en) | 2024-04-11 |
| US20260108513A1 (en) | 2026-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cruz-Burgos et al. | New approaches in oncology for repositioning drugs: the case of PDE5 inhibitor sildenafil | |
| USRE49353E1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| AU2024200203B2 (en) | Methods for the treatment of recurrent glioblastoma (RGBM) | |
| Jhaveri et al. | Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC) | |
| Haus et al. | Spectrum of use and tolerability of 5‐HT3 receptor antagonists | |
| JP2015536964A (en) | Pharmaceutical combinations comprising B-RAF inhibitors and histone deacetylase inhibitors and their use in the treatment of proliferative diseases | |
| JP2016520622A5 (en) | ||
| JP2024510666A5 (en) | ||
| KR101628448B1 (en) | Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer | |
| EP1201247B1 (en) | Treatment of metastatic renal cell carcinoma | |
| Sharma et al. | New acalabrutinib formulation enables co-administration with proton pump inhibitors and dosing in patients unable to swallow capsules (ELEVATE-PLUS) | |
| JP2015514796A (en) | Dexanabinol or a derivative thereof for use in treating cancer at doses ranging from 2 to 30 mg / kg | |
| CN120302972A (en) | Combination of talazoparib and enzalutamide for the treatment of metastatic castration-resistant prostate cancer | |
| EP4087572A1 (en) | Combination therapy for treating cancer | |
| CN116322690A (en) | Combination Drug Anticancer Therapy | |
| RU2025107889A (en) | COMBINATION OF TALAZOPARIB AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | |
| Silvestris et al. | Update on capecitabine alone and in combination regimens in colorectal cancer patients | |
| EP4178566B1 (en) | Satraplatin for use in the treatment of primary central nervous system lymphoma (pcnsl) | |
| US20120283278A1 (en) | Combination | |
| Grothey et al. | 295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial | |
| Nalawade et al. | Olaparib an anticancer drug: A review | |
| Petrylak et al. | EV-301: an open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC) | |
| CN106421796B (en) | Sorafenib combines CCR4 antagonist and is inhibiting the application in cancer growth and transfer | |
| US20190000779A1 (en) | Pharmaceutical formulation | |
| WO2022212631A1 (en) | Treatment of patients metastatic castration-resistant prostate cancer with an androgen receptor antagonist |